AB
Guest dossier
Albert Bourla
business executivepharmacologistveterinarianexecutive
Albert Bourla is a Greek-American veterinarian and businessman known for serving as the chairman and chief executive officer of the pharmaceutical company Pfizer. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla was chief operating officer.
Across 1 conversation, Albert Bourla ranges across public trust, pharmaceutical ethics, COVID-19. Pfizer invested $2.3 billion in developing the COVID-19 vaccine, emphasizing breakthroughs over profit. The FDA's 75-year data withholding request is due to a slow review process, not malintent.
Synthesized by TLexDR from 1 conversation. AI-generated. Report an inaccuracy
The idea map
Albert's intellectual territory
Click a star to read the quotes and jump into the episode.
For the specialist
previewPfizer's $2.3 billion investment in the COVID-19 vaccine highlights a strategic shift towards prioritizing breakthroughs over immediate profit.
#249Albert Bourla: Pfizer CEO
The FDA's 75-year data release request reflects systemic review inefficiencies rather than deliberate obfuscation, impacting public trust.
#249Albert Bourla: Pfizer CEO
The appearance
Every conversation, in order
Reading list
What they pointed you toward
articles
videos
Every idea, by region